SCHEMBL10043906

SCHEMBL10043906

Cc1cc2c(cn1)cc(-c1cc(C(=O)Nc3cccnn3)ccc1C)c(=O)n2C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.45
RAF1 P04049 2/20 0.41
MAPK13 O15264 1/20 0.41
PDGFRA P16234 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
MAPK12 P53778 1/20 0.41
KCNH2 Q12809 1/20 0.41
MAPK11 Q15759 1/20 0.41
SYK P43405 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.40
BRAF P15056 1/20 0.40
BTK Q06187 1/20 0.39
LCK P06239 1/20 0.39
KIT P10721 1/20 0.39
KDR P35968 1/20 0.39
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MTOR P42345 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043912 0.89 NPC1 (0.51) MAPK14RAF1MAPK13PDGFRAMAPKAPK2
SCHEMBL10043926 0.88 MAPK14 (0.45) MAPK14RAF1MAPK13PDGFRAMAPKAPK2
SCHEMBL10043916 0.86 MAPK14 (0.47) MAPK14RAF1MAPK13PDGFRAMAPKAPK2
SCHEMBL10043909 0.85 RAB9A (0.45) MAPK14RAF1MAPK13PDGFRAMAPKAPK2
SCHEMBL10043900 0.85 NPC1 (0.46) MAPK14RAF1MAPK13PDGFRAMAPKAPK2
SCHEMBL502061 0.84 CNR1 (0.48) MAPK14BTKALDH1A1NPC1RAB9A
SCHEMBL10043899 0.84 MAPK14 (0.46) MAPK14RAF1MAPK13PDGFRAMAPKAPK2
SCHEMBL10043901 0.84 KCNQ3 (0.49) MAPK14RAF1MAPK13PDGFRAMAPKAPK2
SCHEMBL10043897 0.83 ALDH1A1 (0.59) MAPK14ALDH1A1NPC1RAB9A
SCHEMBL10043919 0.83 NPC1 (0.50) MAPK14RAF1MAPK13PDGFRAMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MAPK14 117/4885RAF1 11/4885MAPK13 106/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC MAPK14 117/4885RAF1 11/4885MAPK13 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.